Senior Director--External Innovation at Eli Lilly and Company

Shanghai, Shanghai, China

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Broad understanding of Lilly pipeline and portfolio strategy to capture external ecosystem trends and identify strategic/technical opportunities in China/AP region
Ability to leverage understanding of external parties' strengths complementary to Lilly pipeline to fulfill pipeline needs
In-depth understanding of the biomedical innovation ecosystem in China/AP region to inform Lilly external innovation strategy
Expertise in medical/clinical development, ADMET, formulation, CMC, and other cross-discipline areas
Ability to lead identification, rigorous assessment, and due diligence of in-licensing opportunities, including forming DD teams and overseeing local efforts
Experience collaborating with R&D teams across therapeutic areas (Diabetes/Obesity/Complications, Neuroscience, Immunology, Oncology, Genetic Medicines), Corporate BD, External Innovation, Molecule Innovation Hub, and China affiliate

Responsibilities

Lead identification and objective assessment of potential in-licensing opportunities, including medical/clinical development assessments for clinical-stage assets
Lead and coordinate local due diligence with sites/hospitals, form DD teams, and oversee local DD efforts
Partner with LCDDMAC and ExploR&D teams to form/execute strategy leveraging China infrastructure for fast-tracking asset development
Partner with TA S&E team to co-lead/participate in partnering meetings/visits with senior leadership, functional groups, BD, and diligence teams
Partner with TA S&E team to co-lead development and execution of project concepts with external groups
Partner with TA S&E team to co-lead communication of technical evaluation results to internal/external stakeholders
Lead development of relationships within external pharmaceutical community in A/P region (pharma/biotech companies, research institutes, academic hospitals, scientific organizations)
Liaise with global function leaders and lead partnership efforts in A/P region per Lilly’s interests
Oversee branding efforts of LCIP and represent Lilly at external events
Oversee development/maintenance of LCIP portfolio projects, monitor progress, and coordinate alliance management with TAs
Partner with External Innovation team to co-lead/support implementation of Catalyst360, Lilly Gateway Labs, and Venture investments in A/P region
Work with transaction team to inform partnership strategy, facilitate negotiations, and communicate with external parties
Ensure integration of efforts through effective teamwork and collaboration with Lilly groups

Skills

Business Development

Strategic Planning

Pipeline Evaluation

In-Licensing

Opportunity Assessment

R&D Collaboration

Innovation Scouting

Portfolio Strategy

Therapeutics Expertise

Biomedical Ecosystem Analysis

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free